Cargando…

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid

BACKGROUND: To assess prognostic and predictive effects of clinical and biochemical factors in our published randomized study of a weekly low dose (metronomic arm) versus a conventional dosage of zoledronic acid (conventional arm) in breast cancer patients with bone metastases. METHODS: Treatment ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Xinmin, Xu, Xiaofeng, Zhang, Qunling, Jia, Zhen, Sun, Si, Zhang, Jian, Wang, Biyun, Wang, Zhonghua, Hu, Xichun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3196722/ https://www.ncbi.nlm.nih.gov/pubmed/21936956 http://dx.doi.org/10.1186/1471-2407-11-403

Ejemplares similares

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
por: Wang, Leiping, et al.
Publicado: (2011)

Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2017)

Dosing of zoledronic acid with its anti-tumor effects in breast cancer
por: Zhao, Xinmin, et al.
Publicado: (2015)

An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer
por: Jia, Zhenya, et al.
Publicado: (2018)

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
por: Sun, Si, et al.
Publicado: (2014)

Cryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases
por: LI, FENQIANG, et al.
Publicado: (2014)

Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Xie, Yizhao, et al.
Publicado: (2021)

Phase II Study of Pseudomonas aeruginosa-Mannose-Sensitive Hemagglutinin in Combination with Capecitabine for Her-2–Negative Metastatic Breast Cancer Pretreated with Anthracycline and Taxane
por: Lv, Fangfang, et al.
Publicado: (2015)

Zoledronic acid for prevention of bone loss in patients receiving bariatric surgery
por: Liu, Yi, et al.
Publicado: (2021)

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
por: Alcaraz, A, et al.
Publicado: (2013)

Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy
por: Huang, Ching-Wen, et al.
Publicado: (2021)

Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer
por: Cao, Jun, et al.
Publicado: (2022)

Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors
por: Zhao, Xinmin, et al.
Publicado: (2022)

Anti-angiogenic and anti-tumor effects of metronomic use of novel liposomal zoledronic acid depletes tumor-associated macrophages in triple negative breast cancer
por: Cai, Xin-Jun, et al.
Publicado: (2017)

Effect of cervus and cucumis polypeptide combined with zoledronic acid on bone metabolic biochemical markers in glucocorticoids – Induced osteoporosis patients
por: Han, Dacheng, et al.
Publicado: (2019)

Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
por: Gong, Chengcheng, et al.
Publicado: (2017)

Effects of zoledronic acid and ibandronate in the treatment of cancer pain in rats with lung cancer combined with bone metastases
por: Wang, Gengshen, et al.
Publicado: (2018)

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
por: Pietrantonio, Filippo, et al.
Publicado: (2016)

Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases
por: Quattrocchi, Carlo C., et al.
Publicado: (2012)

GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2017)

Zoledronate combined metal-organic frameworks for bone-targeting and drugs deliveries
por: Pan, Yixiao, et al.
Publicado: (2022)

Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole
por: Sun, Shengliang, et al.
Publicado: (2016)

Metronomics for thymic carcinoma
por: del Toro, Jacobo Muñoz, et al.
Publicado: (2014)

Development of fever following first administration of zoledronate as a prognostic factor in advanced non-small cell lung cancer patients with bone metastases
por: Izumi, Hiroki, et al.
Publicado: (2017)

Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer
por: Jin, Jia, et al.
Publicado: (2018)

The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer
por: Hadji, Peyman, et al.
Publicado: (2012)

Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China
por: Liu, Chang, et al.
Publicado: (2020)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Rader, Michael, et al.
Publicado: (2012)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Xie, Jipan, et al.
Publicado: (2011)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
por: Zhang, Jian, et al.
Publicado: (2015)

A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer
por: Zhao, Yannan, et al.
Publicado: (2017)

Early changes in soluble intracellular adhesion molecule‐1 as prognostic biomarkers to immune checkpoint inhibitor
por: Ji, Dongmei, et al.
Publicado: (2023)

Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis
por: Xie, Yizhao, et al.
Publicado: (2022)

The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials
por: Zhang, Zhicai, et al.
Publicado: (2017)

Metronomics: Intrinsic Anakoinosis Modulator?
por: Nicolas, André, et al.
Publicado: (2018)

Metronomic Chemotherapy in Prostate Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2022)

Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L
por: Liu, Rujiao, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_b0nqnbfbpdrt67d98vnss1jq6l